<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3606">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697709</url>
  </required_header>
  <id_info>
    <org_study_id>6623</org_study_id>
    <secondary_id>1R01DA031826</secondary_id>
    <nct_id>NCT01697709</nct_id>
  </id_info>
  <brief_title>Quetiapine Pharmacotherapy for Cannabis Dependence</brief_title>
  <acronym>QUEST</acronym>
  <official_title>Quetiapine Pharmacotherapy for Cannabis Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite a benign public perception, marijuana use disorders represent a significant public&#xD;
      health problem. The development of safe and effective pharmacotherapies for marijuana&#xD;
      dependence is an important unmet public health need. Quetiapine, an effective atypical&#xD;
      antipsychotic that acts by blocking serotonin type 2A, dopamine type 2, histamine type 1, and&#xD;
      adrenergic receptors, is a promising treatment for substance use disorders. In animal models,&#xD;
      quetiapine blocks the enhancement of reward by cocaine, which is likely due to its actions on&#xD;
      both dopamine and non-dopamine neurotransmission. Clinical studies of quetiapine have shown&#xD;
      benefit for the treatment of alcohol and cocaine use disorders.&#xD;
&#xD;
      Conceptually, the clinically prominent effects of quetiapine, namely sedation, anxiolysis,&#xD;
      mood stabilization and appetite stimulation, are a good match for the symptoms of marijuana&#xD;
      withdrawal. Most importantly, an open-label dose-finding study of quetiapine for the&#xD;
      treatment of marijuana dependence conducted by our research group determined that quetiapine&#xD;
      was well-tolerated and associated with reductions in marijuana use indicating that it is a&#xD;
      promising agent deserving of further study in marijuana-dependent outpatients.&#xD;
&#xD;
      The proposed research project is a randomized double-blind placebo-controlled clinical trial&#xD;
      to evaluate the efficacy of quetiapine for the treatment of marijuana dependence over a&#xD;
      12-week period. All participants will receive Medical Management, a medication adherence&#xD;
      focused psychosocial intervention that facilitates compliance with study medication and other&#xD;
      study procedures, promotes abstinence from marijuana and other substances, and encourages&#xD;
      mutual-support group attendance. All participants will receive voucher incentives for&#xD;
      compliance with study visit attendance, returning study medication bottles, and completing&#xD;
      other study procedures, with the objective of achieving a highly compliant sample. The goal&#xD;
      of this phase II clinical trial is to build on our promising open-label pilot study results&#xD;
      and examine the efficacy of quetiapine on participants' marijuana consumption under&#xD;
      placebo-controlled double-blind conditions using an abstinence-initiation model, where&#xD;
      participants will be using marijuana regularly at study entry, reduce their use, and then&#xD;
      achieve abstinence. The specific aims of the projects are to determine whether quetiapine is&#xD;
      superior to placebo in 1) reducing marijuana use and 2) achieving abstinence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a 12-week randomized double-blind placebo-controlled clinical trial, we will evaluate the&#xD;
      efficacy of quetiapine for the treatment of marijuana dependence in 150 outpatients.&#xD;
      Participants will be randomly assigned to treatment under double-blind conditions with either&#xD;
      a fixed dosing schedule of quetiapine or placebo. All participants will receive Medical&#xD;
      Management, a medication adherence focused psychosocial intervention that facilitates&#xD;
      compliance with study medication and other study procedures, and promotes abstinence from&#xD;
      marijuana and other substances. All participants will receive progressive voucher incentives&#xD;
      for compliance with study visit attendance and completing other study procedures, with the&#xD;
      objective of achieving a highly compliant sample.&#xD;
&#xD;
      The results of a dose-finding pilot study of quetiapine for the treatment of marijuana&#xD;
      dependence (see Preliminary Studies) suggests that the ideal dosing for the proposed project&#xD;
      is a single 300 mg dose every evening, achieved after a gradual three-week titration.&#xD;
      Clinical experience with this medication for treatment of marijuana dependence indicates that&#xD;
      a gradual upward titration of dose is advisable to maximize tolerability and that morning&#xD;
      dosing was poorly tolerated. Quetiapine (immediate release formulation) will be administered&#xD;
      in 25 and 100 mg capsules; placebo capsules will appear identical to the quetiapine capsules.&#xD;
      Participants in both treatment arms will take the same number of pills on the same schedule.&#xD;
      Study medication will be dispensed on a weekly basis starting with the baseline visit.&#xD;
      Quetiapine will be titrated over a three-week period to the target dose of 300 mg or the&#xD;
      maximum tolerated dose. The research psychiatrist will make dose reductions for tolerability&#xD;
      if necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2012</start_date>
  <completion_date type="Actual">April 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study</measure>
    <time_frame>12 weeks or length of participants involvement</time_frame>
    <description>The median daily dollar value of marijuana used averaged over a one-week period for each of the 12 weeks as recorded by the Timeline Followback method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Stratified by Marijuana Abstinence Days Per Week</measure>
    <time_frame>12 weeks or length of participation</time_frame>
    <description>The number of abstinent days per week over the 12 weeks of study as recorded by the Timeline Followback method. High Use group defined as 0-2 abstinent days per week, Medium Use Group as 3-5 abstinent days per week and Low Use Group as 6-7 abstinent days per week.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine pharmacotherapy for cannabis dependence</description>
    <arm_group_label>quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matched Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets DSM-IV-TR criteria for current marijuana dependence&#xD;
&#xD;
          2. Reports using marijuana an average of 5 days per week over the past 28 days&#xD;
&#xD;
          3. Between the ages of 18 and 60&#xD;
&#xD;
          4. Able to provide informed consent and comply with study procedures&#xD;
&#xD;
          5. Seeking treatment for cannabis dependence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lifetime DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar&#xD;
             disorder.&#xD;
&#xD;
          2. Current DSM-IV criteria for any other psychiatric disorder that may, according to&#xD;
             investigator's judgment, require either pharmacological or non-pharmacological&#xD;
             intervention over the course of the study.&#xD;
&#xD;
          3. Patients prescribed psychotropic medications.&#xD;
&#xD;
          4. History of allergic reaction, intolerance, or hypersensitivity to Quetiapine.&#xD;
&#xD;
          5. Pregnancy, lactation, or failure to use adequate contraceptive methods in female&#xD;
             patients who are currently engaging in sexual activity with men.&#xD;
&#xD;
          6. Unstable medical conditions, such as poorly controlled hypertension which might make&#xD;
             participation hazardous.&#xD;
&#xD;
          7. Diabetes (whether controlled or not), meeting criteria for metabolic syndrome as&#xD;
             defined by the NCEP (any 3 of the following: a. obesity [waist circumference &gt; 40&#xD;
             inches], b. hyperglycemia [fasting glucose &gt; 100 mg/dl or Rx], c. dyslipidemia [TG &gt;&#xD;
             150 mg/dl or Rx], d. dyslipidemia [HDL cholesterol; 40 mg/dl (male), 50 mg/dl (female)&#xD;
             or Rx], e. hypertension [130 mmHg systolic or &gt; 85 mmHg diastolic or Rx]. Participants&#xD;
             with a BMI &gt; 35 will be excluded.&#xD;
&#xD;
          8. Current DSM-IV diagnosis of an alcohol or substance use disorder (abuse or dependence)&#xD;
             other than marijuana or nicotine dependence.&#xD;
&#xD;
          9. Positive confirmed result on urine toxicology screen.&#xD;
&#xD;
         10. Are legally mandated to participate in a substance use disorder treatment program.&#xD;
&#xD;
         11. Increased risk for suicide.&#xD;
&#xD;
         12. QTc prolongation (screening electrocardiogram with Qtc &gt; 450 msec for men, QTc &gt; 470&#xD;
             msec for women) or history of QTc prolongation or using concomitant medications which&#xD;
             prolong QTc interval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John J Mariani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University/NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu</url>
    <description>Study web site</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <results_first_submitted>January 17, 2019</results_first_submitted>
  <results_first_submitted_qc>January 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2019</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>John Mariani MD</investigator_full_name>
    <investigator_title>research psychiatrist</investigator_title>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>marijuana</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01697709/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01697709/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were randomized to one of the treatment arms at time of enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo medication&#xD;
Placebo: placebo capsules</description>
        </group>
        <group group_id="P2">
          <title>Quetiapine</title>
          <description>Quetiapine treatment&#xD;
Quetiapine: Quetiapine pharmacotherapy for cannabis dependence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo medication&#xD;
Placebo: placebo capsules</description>
        </group>
        <group group_id="B2">
          <title>Quetiapine</title>
          <description>Quetiapine treatment&#xD;
Quetiapine: Quetiapine pharmacotherapy for cannabis dependence</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="8.7"/>
                    <measurement group_id="B2" value="32.7" spread="9.5"/>
                    <measurement group_id="B3" value="32.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mood/anxiety disorder</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marijuana using days past 28 days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="2.1"/>
                    <measurement group_id="B2" value="26.4" spread="2.5"/>
                    <measurement group_id="B3" value="26.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study</title>
        <description>The median daily dollar value of marijuana used averaged over a one-week period for each of the 12 weeks as recorded by the Timeline Followback method</description>
        <time_frame>12 weeks or length of participants involvement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo medication&#xD;
Placebo: placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>Quetiapine treatment&#xD;
Quetiapine: Quetiapine pharmacotherapy for cannabis dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study</title>
          <description>The median daily dollar value of marijuana used averaged over a one-week period for each of the 12 weeks as recorded by the Timeline Followback method</description>
          <units>dollars</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" lower_limit="5.42" upper_limit="21.25"/>
                    <measurement group_id="O2" value="7.00" lower_limit="3.18" upper_limit="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="2.86" upper_limit="22.00"/>
                    <measurement group_id="O2" value="8.00" lower_limit="3.02" upper_limit="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" lower_limit="2.64" upper_limit="17.69"/>
                    <measurement group_id="O2" value="5.86" lower_limit="3.29" upper_limit="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" lower_limit="1.61" upper_limit="16.25"/>
                    <measurement group_id="O2" value="5.71" lower_limit="2.57" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" lower_limit="1.07" upper_limit="17.86"/>
                    <measurement group_id="O2" value="4.29" lower_limit="1.43" upper_limit="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" lower_limit="0.96" upper_limit="13.82"/>
                    <measurement group_id="O2" value="4.11" lower_limit="1.32" upper_limit="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" lower_limit="1.03" upper_limit="12.59"/>
                    <measurement group_id="O2" value="3.57" lower_limit="1.43" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" lower_limit="1.12" upper_limit="12.26"/>
                    <measurement group_id="O2" value="3.43" lower_limit="1.18" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" lower_limit="1.03" upper_limit="11.96"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.43" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" lower_limit="0.00" upper_limit="12.32"/>
                    <measurement group_id="O2" value="2.86" lower_limit="0.29" upper_limit="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="0.00" upper_limit="11.79"/>
                    <measurement group_id="O2" value="2.86" lower_limit="0.00" upper_limit="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.00" upper_limit="12.29"/>
                    <measurement group_id="O2" value="2.14" lower_limit="0.00" upper_limit="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Stratified by Marijuana Abstinence Days Per Week</title>
        <description>The number of abstinent days per week over the 12 weeks of study as recorded by the Timeline Followback method. High Use group defined as 0-2 abstinent days per week, Medium Use Group as 3-5 abstinent days per week and Low Use Group as 6-7 abstinent days per week.</description>
        <time_frame>12 weeks or length of participation</time_frame>
        <population>participants were included in the weekly analysis who were still active in the trial at each given week.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo medication&#xD;
Placebo: placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>Quetiapine treatment&#xD;
Quetiapine: Quetiapine pharmacotherapy for cannabis dependence</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Stratified by Marijuana Abstinence Days Per Week</title>
          <description>The number of abstinent days per week over the 12 weeks of study as recorded by the Timeline Followback method. High Use group defined as 0-2 abstinent days per week, Medium Use Group as 3-5 abstinent days per week and Low Use Group as 6-7 abstinent days per week.</description>
          <population>participants were included in the weekly analysis who were still active in the trial at each given week.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>high use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>medium use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>low use</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>over 12 weeks of study or length of participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo medication&#xD;
Placebo: placebo capsules</description>
        </group>
        <group group_id="E2">
          <title>Quetiapine</title>
          <description>Quetiapine treatment&#xD;
Quetiapine: Quetiapine pharmacotherapy for cannabis dependence</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>&gt;130 or &gt; 85</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidemia</sub_title>
                <description>TG &gt;150mg</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>&gt;100 mg</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>john mariani. MD</name_or_title>
      <organization>NYSPI</organization>
      <phone>212-923-3031</phone>
      <email>John.mariani@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

